Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/16319

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/16319

题名:	Immunotherapy: rAAV2 expressing interleukin-15 inhibits HeLa cell tumor growth in mice
作者:	余永倫;Yu, Yung-luen;Yiang, Giou-Teng;Harn, Horng-Jyh;Hu, Sheng-Chuan;Hung, Yu-Ting;Hsieh, Chia-Jung;Lin, Shinn-Zong;Wei, Chyou-Wei
贡献者:	生物科技學系
日期:	2009-05
上传时间:	2012-11-23 09:11:25 (UTC+0)
摘要:	Human interleukin-15 (hIL15) has anti-tumor activities, but it is not convenient for tumor treatment because of its short half-life. A gene therapy for mouse lung cancer using an adenovirus vector expressing IL15 has been reported. However, adenovirus vector-mediated gene therapy can provoke cellular toxicity and inflammatory reactions. The recombinant adenovirus-associated vector 2 (rAAV2) is safer due to minimal cellular toxicity and immune response. In order to demonstrate that gene therapy can be used safely and successfully for human cancer treatment, the rAAV2 expressing hIL15 gene (rAAV2-hIL15) is applied for human cervical cancer, HeLa cell, in this study. This study successfully demonstrates that rAAV2-hIL15 can express IL15 with bioactivities in vitro and in vivo. In conclusion, our studies show that human cervical cancers are inhibited on animal model with rAAV2-hIL15 treatment and provide a safer and important reference for human cancer gene therapy.
關聯:	JOURNAL OF BIOMEDICAL SCIENCE
显示于类别:	[生物科技學系] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	390	检视/开启

在ASIAIR中所有的数据项都受到原著作权保护.